Life after a kidney transplant and why early detection matters

East Africa faces an escalating public health emergency that remains largely invisible to international investors: the dual burden of kidney disease and metabolic disorders, compounded by late-stage diagnosis and fragmented treatment infrastructure. This convergence represents both a humanitarian crisis and an underappreciated market opportunity for European healthcare entrepreneurs willing to navigate Africa's complex regulatory and distribution landscapes. The epidemiology tells a stark story. Uncontrolled diabetes and hypertension—conditions that disproportionately affect working-age adults in Sub-Saharan Africa—are the leading causes of chronic kidney disease (CKD) across the region. Yet prevalence estimates likely understate the true burden. Most African nations lack comprehensive screening programs, meaning patients typically present at Stage 4 or Stage 5 CKD, when kidney function has already deteriorated by 75% or more. By this point, dialysis or transplantation becomes unavoidable—interventions far more expensive and resource-intensive than early intervention protocols available in European healthcare systems. The treatment landscape further illuminates the investment opportunity. While kidney transplantation offers superior long-term outcomes and quality-of-life metrics compared to dialysis, Africa's transplant infrastructure remains severely constrained. Shortage of organs, limited surgical expertise, expensive immunosuppressive medications, and weak post-transplant monitoring systems mean transplant programs operate at only 5-10% of their potential capacity in most East African